Neurocrine Biosciences Provides Update on Phase 3 Study of Valbenazine in Dyskinetic Cerebral Palsy

Core Insights - Neurocrine Biosciences announced that its Phase 3 KINECT-DCP study of valbenazine for dyskinetic cerebral palsy did not meet primary or key secondary endpoints [1][2] Company Overview - Neurocrine Biosciences is a biopharmaceutical company focused on neuroscience, dedicated to developing treatments for neurological, neuroendocrine, and neuropsychiatric disorders [7] - The company has a portfolio that includes FDA-approved treatments for tardive dyskinesia and chorea associated with Huntington's disease, among others [7] Study Details - The KINECT-DCP study was the largest double-blind placebo-controlled trial for dyskinetic cerebral palsy, evaluating 14 weeks of valbenazine treatment against placebo [2][5] - The primary objective was to assess the efficacy of valbenazine in improving chorea in participants aged 6 to 70 years with dyskinetic cerebral palsy [5] Drug Information - Valbenazine is a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, previously approved for tardive dyskinesia and more recently for chorea associated with Huntington's disease [6] - The safety profile of valbenazine in the study was consistent with established data [2]